The IL11 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population in which the IL11 gene has been disrupted in the human 143B osteosarcoma cell line. This heterogeneous knockout pool serves as a robust tool for studying IL11-dependent biological processes without clonal selection artifacts. The polyclonal format retains cellular diversity, offering a more representative model of tumor cell responses.
The 143B cell line is a highly tumorigenic and metastatic human osteosarcoma model with osteoblast-like characteristics. Widely used in bone cancer research, it enables investigation of tumor growth, invasion, and metastatic dissemination, particularly to bone and lung. Its aggressive phenotype and compatibility with genetic manipulation make it an ideal host for gene knockout studies.
IL11 encodes a cytokine from the IL-6 family that signals through a heterodimeric receptor complex of IL11RA and GP130. Ligand binding activates JAK/STAT and MAPK/ERK cascades, along with PI3K/AKT signaling. IL11 expression is induced by TGF-??1, IL-1, and TNF-??. Downstream, activated STAT3 and ERK1/2 promote transcription of BCL2, CCND1, VEGF, MMP2, and MMP9, driving proliferation, survival, migration, and matrix remodeling. IL11 thus plays a central role in inflammation, bone remodeling, and cancer progression.
In osteosarcoma, IL11 contributes to a pro-metastatic microenvironment via autocrine and paracrine mechanisms. The 143B cells endogenously express IL11 and its receptor components, making this knockout model physiologically relevant. Disruption of IL11 allows dissection of its effects on osteosarcoma cell proliferation, apoptosis resistance, motility, and invasion, as well as tumor-stromal interactions involved in bone metastasis.
These polyclonal knockout cells are suitable for diverse applications, including RT-qPCR and western blot analyses of IL11 and downstream phospho-STAT3/pERK, functional assays like wound-healing migration and Matrigel invasion, and in vivo xenograft studies of tumor growth and metastasis. They also support phospho-signaling profiling, RNA-seq, and screening of IL11 pathway inhibitors. For additional information, please contact Ascent Research.
